{"id":"NCT01808651","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Fluoxetine in Major Depressive Disorder (MDD) Long-Term Dosing","officialTitle":"A Phase 3, Open-label, Long-Term Study to Evaluate the Safety of LY110140 Once Daily Dosing for 52-week in Japanese Patients With Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-05","primaryCompletion":"2015-03","completion":"2015-03","firstPosted":"2013-03-11","resultsPosted":"2015-11-26","lastUpdate":"2015-11-26"},"enrollment":200,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"Fluoxetine","otherNames":["LY110140","Fluoxetine Hydrochloride","Prozac","Sarafem"]}],"arms":[{"label":"Fluoxetine","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the safety and effectiveness of fluoxetine flexible dosing in the treatment of MDD in adult Japanese participants.\n\nParticipants who complete the short-term treatment phase of Study B1Y-JE-HCLV (NCT#: NCT01808612) will be allowed to enroll in this study, and receive fluoxetine treatment for an additional 52 weeks.","primaryOutcome":{"measure":"Number of Participants With Adverse Events (AEs) or Serious AEs (SAEs)","timeFrame":"Baseline through Week 52.","effectByArm":[{"arm":"PLA/FLX","deltaMin":2,"sd":null},{"arm":"FLX20/FLX","deltaMin":1,"sd":null},{"arm":"FLX40/FLX","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":9},"locations":{"siteCount":16,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":98},"commonTop":["Nasopharyngitis","Headache","Somnolence","Nausea","Diarrhoea"]}}